the association of the her2dx signatures with survival in tnbc
Published 2 years ago • 90 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:22
immunological signatures to predict outcomes in patients with tnbc
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
0:41
recent advances in targeted therapies for tnbc
-
1:22
her2dx risk-score in early-stage her2-positive breast cancer
-
2:07
the association between jnk activity and immunotherapeutic efficacy of io in tnbc
-
1:42
her2dx and pcr in her2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
-
4:26
independent validation of the her2dx genomic test in her2-positive breast cancer
-
1:15
the value of early diagnosis in amyloidosis and the impact of a delayed diagnosis for patients
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
0:41
the importance of brca-1 testing in triple negative breast cancer
-
1:15
clinical implications of progress in tnbc therapies
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
2:05
treatment advances in tnbc
-
3:49
her2dx: a new diagnostic tool for early-stage her2 positive breast cancer
-
2:30
impassion130: immunotherapy for tnbc
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
2:38
olaparib durvalumab as a chemotherapy-free maintenance strategy in platinum treated advanced tnbc
-
1:29
takeaways on the management of early-stage tnbc
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355